The search for biomarkers of primary resistance to ICIs led us and other researchers to explore the role of circulating immune cells, given that data on PD-L1 and tumor mutational burden (TMB) are not fully consistent for patients’ selection. This evidence concerns the gene CD274 and neoplasm.